DEVELOPMENT AND EVALUATION OF FAST DISSOLVING TABLETS & COMPARATIVE IN-VITRO DISSOLUTION STUDY OF VARIOUS MARKETED BRANDS OF ATENOLOL TABLETS
Abstract
Atenolol is a beta blocker commonly prescribed as a hypertension and for the treatment of angina. The current study was undertaken with the aim of analyzing quality of commercially available brands of atenolol tablets available in market. To assess the quality, locally available 100 mg atenolol tablet of four different manufacturers were selected and certain physico-chemical parameters like weight variation, hardness, friability, disintegration time and dissolution profile etc. were evaluated using in-vitro analytical methods. All the tablet brands met the requirements of IP as they showed acceptable weight variation and friability. Brands were slightly different in hardness, disintegration time and dissolution profile from each other. The hardness of all the brands was found to be in the range of2.250±1.18 to 4.21±0.11 kg-ft. In water medium the disintegration time of all brands were found to be 0.57±0.45 to 2.22±0.23 min. Five out of seven brands showed better dissolution profile as they released more than 90% drug in 30 min. The study revealed that most of the marketed atenolol tablets met the BP standards for physico-chemical properties which are the indicators of drug quality. It can be concluded that drug products should always comply standard quality parameters that are the prerequisites for getting satisfactory clinical effects.
Key words: Atenolol, hypertension, disintegration, dissolution
References
Dakkuri, A.; Shah, A. C. Pharmaceutical Technology 1982, 6, 28–47.
Dissolution 711 . In United States Pharmacopeia and National Formulary USP 29–NF 24; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005; pp 123–135.
Subcommittee on Dissolution Calibration, Pharmaceutical Research and Manufacturers of America (PhRMA). Dissolution Calibration: Recommendations for Reduced Chemical Testing and Enhanced Mechanical Calibration. Pharm. Forum 2000, 26 (4), 1149–1166.
Gray, V. A.; Brown, C. K.; Dressman, J. B.; Leeson, L. J. A New General Information Chapter on Dissolution. Pharm. Forum 2001, 27 (6), 3432–3439.
Ross, M. S. F.; Rasis, M. Mega Paddle—A Recommendation to Modify Apparatus 2 Used in the USP General Test for Dissolution 711 . Pharm. Forum 1998, 24 (3), 6351–6359.
Drug Release 724 . In United States Pharmacopeia and National Formulary USP 29–NF 24; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005; pp 2690–2693.
Intrinsic Dissolution 1087 . In United States Pharmacopeia and National Formulary USP 29–NF 24; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005; pp 2923–2924.
Dissolution Testing of Immediate Release Solid Oral Dosage Forms; Guidance for Industry; U.S. Department of Health and Human Services, Food and Drug Administration, U.S. Government Printing Office: Washington, DC, August 1997.
http://en.wikipedia.org /wiki/Alprazolam; Accessed on Nov. 12th, 2014.
www.xanaxxr.com/utilities/xanaxxr.pdf; Accessed on Nov. 12th, 2014.
Lachman L, Lieberman H A and Kanig JL,"The theory and practice of industrial pharmacy", 3rd Ed., Philadelphia: Lea and Febiger, 1986, 297-304.
Costa P, and Sousa Lobo JM; Modeling and comparison of dissolution profiles, Eur J Pharm Sci. 2001 May;13(2):123-33.
Costa P.; An alternative method to the evaluation of similarity factor in dissolution testing, Int J Pharm. 2001 Jun 4;220(1-2):77-83.
Siepmann J, Siepmann F.; Mathematical modeling of drug dissolution, Int J Pharm. 2013 Aug 30;453(1):12-24. doi: 10.1016/j.ijpharm.2013.04.044. Epub 2013 Apr 22.
Prajapati ST, Formulation and evaluation of sublingual tablets of nitrendipine; IJPRBS, 2014; Volume 3(3): 496-508
Fawzia Khan, Comparison of In Vitro Dissolution Tests for Commercially Available Aspirin Tablets; Dissolution Technologies, February 2013dx.doi.org/10.14227/DT200113P48
Xochimilco, Colonia Villa Quietud, México D.F., México.; ; Compared of Dissolution Profiles for Albendazole Tablets Using USP Apparatus 2 and 4. Drug Development and Industrial Pharmacy (Impact Factor: 2.1). 09/2003; 29(7):777-84. DOI: 10.1081/DDC-120021777
Lalic M1, Pilipovic A, Golocorbin-Kon S, Gebauer-Bukurov K, Bozic K, Mikov M, Cvejic J. Comparison of dissolution profiles and serum concentrations of two lamotrigine tablet formulations, Drugs R D. 2011;11(1):53-60. doi: 10.2165/11588260-000000000-00000.
USP/NF: the United States Pharmacopoeia/National Formulary. USP 24th Ed., NF 19th Ed., New York; Twinbrooke Parkway, 2000, 64, 1885-2002.
Banakar, UV, "Pharmaceutical Dissolution Testing", 1st Ed., Marcel Dekker Inc. NewYork, 1992, 103.
O’neil MJ,”The Merck Index”, 13th Ed., Washington, Merck and Co.Inc,Whitehouse station, NY, USA, 2001, 310-311.
